Chennai, Mar 30: Biocon Limited announced the appointment of Shreehas Tambe as its Chief Executive Officer & Managing Director, effective April 1, 2026, following approvals from the Nomination & Remuneration Committee and the Board of Directors.
As the first CEO of the integrated Biocon, Tambe will lead the combined platform spanning biosimilars and generics, strengthening the company’s ability to scale operations and compete effectively in global markets. The company also announced the appointment of Kedar Upadhye as Chief Financial Officer.
This leadership transition follows the integration of Biocon Biologics Limited as a wholly owned subsidiary of Biocon Limited, creating a unified and simplified corporate structure. The integrated entity is positioned to expand its leadership across key therapeutic areas including diabetes, obesity, oncology, and immunology, supported by a diversified portfolio of biosimilars, insulins, complex generics, and peptides, including GLP-1 therapies.
Commenting on the appointment, Kiran Mazumdar-Shaw, Executive Chairperson, Biocon Limited, said,
“Biocon has consistently grown by anticipating patient needs and building ahead of the curve. With the integration of our generics and biosimilars businesses, we are creating a uniquely positioned, globally scaled biopharma enterprise. Shreehas has been at the forefront of this transformation, leading key strategic milestones, including the acquisition and integration of the Viatris biosimilars business and expanding our global footprint. I am confident he will drive disciplined execution and sustained global leadership.”
She also acknowledged the contributions of Siddharth Mittal, stating,
“I would like to thank Siddharth for his tremendous contributions to Biocon. Since joining in 2013, he has played a pivotal role in shaping the company’s growth trajectory. He will now transition to another leadership role within the Biocon Group.”
Speaking on his appointment, Shreehas Tambe said,
“It is an honor to lead Biocon at such a pivotal moment as we integrate our biologics and generics businesses to build a leading global medicines company. Our focus will be on strengthening our foundation, consolidating our business, and accelerating sustainable growth while continuing to expand access to life-saving treatments worldwide.”
With this strategic leadership transition, Biocon Limited aims to further strengthen its global presence and reinforce its commitment to delivering affordable, high-quality healthcare solutions.
